---
reference_id: "PMID:38157881"
title: "Behavioral or neuropsychiatric symptoms of Alzheimer's disease: from psychopathology to pharmacological management."
authors:
- Teixeira AL
- Rocha NP
- Gatchel J
journal: Arq Neuropsiquiatr
year: '2023'
doi: 10.1055/s-0043-1777774
content_type: abstract_only
---

# Behavioral or neuropsychiatric symptoms of Alzheimer's disease: from psychopathology to pharmacological management.
**Authors:** Teixeira AL, Rocha NP, Gatchel J
**Journal:** Arq Neuropsiquiatr (2023)
**DOI:** [10.1055/s-0043-1777774](https://doi.org/10.1055/s-0043-1777774)

## Content

1. Arq Neuropsiquiatr. 2023 Dec;81(12):1152-1162. doi: 10.1055/s-0043-1777774.
Epub  2023 Dec 29.

Behavioral or neuropsychiatric symptoms of Alzheimer's disease: from 
psychopathology to pharmacological management.

Teixeira AL(1)(2), Rocha NP(3), Gatchel J(4)(5)(6).

Author information:
(1)University of Texas University of Texas Health Science Center, McGovern 
Medical School, Department of Psychiatry and Behavioral Sciences, 
Neuropsychiatry Program, Houston, Texas, United States.
(2)Faculdade Santa Casa Belo Horizonte, Belo Horizonte MG, Brazil.
(3)University of Texas Health Science Center, McGovern Medical School, 
Department of Neurology, Houston, Texas, United States.
(4)Massachusetts General Hospital, Department of Psychiatry, Boston, 
Massachusetts, United States.
(5)Baylor College of Medicine, Department of Psychiatry, Houston, Texas, United 
States.
(6)Michael E. Debakey VA Medical Center, Houston, Texas, United States.

Neuropsychiatric or behavioral symptoms of dementia encompass a series of 
disorders, such as anxiety, depression, apathy, psychosis, and agitation, all 
commonly present in individuals living with dementia. While they are not 
required for the diagnosis of Alzheimer's disease (AD), they are ubiquitously 
present in all stages of the disease, contributing to negative clinical 
outcomes, including cognitive decline, functional disability, and caregiver 
burden. Neuropsychiatric symptoms have been conceptualized not only as risk 
factors but as clinical markers of decline along the AD spectrum. The concept of 
"mild behavioral impairment", the behavioral correlate of mild cognitive 
impairment, has been proposed within this framework. The first steps in the 
management of behavioral symptoms in AD involve defining the target and 
investigating potential causes and/or aggravating factors. Once these factors 
are addressed, non-pharmacological approaches are preferred as first-line 
interventions. Following the optimization of anticholinesterase treatments, 
specific pharmacological approaches (e.g., antidepressants, antipsychotics) can 
be considered weighing potential side effects.

Publisher: Sintomas neuropsiquiátricos ou comportamentais de demência envolvem 
uma série de condições, como ansiedade, depressão, apatia, psicose e agitação, 
frequentemente observadas em indivíduos com demência. Embora esses sintomas não 
sejam necessários para o diagnóstico da doença de Alzheimer, estão presentes em 
todas as fases ou estágios da doença, contribuindo negativamente para o declínio 
cognitivo, comprometimento funcional e sobrecarga do cuidador. Os sintomas 
neuropsiquiátricos têm sido conceituados não apenas como fatores de risco, mas 
também como marcadores clínicos de progressão da doença de Alzheimer. O 
construto “comprometimento comportamental leve”, correlato comportamental do 
comprometimento cognitive leve, tem sido proposto nesse contexto. Os primeiros 
passos na abordagem dos sintomas comportamentais da doença de Alzheimer envolvem 
definir os alvos-terapêuticos e investigar potenciais causas ou fatores 
agravantes. Após intervir nesses fatores, abordagens não farmacológicas 
constituem a primeira linha de intervenção. Depois da otimização do tratamento 
anticolinesterásico, terapias farmacológicas específicas (por exemplo, 
antidepressivos, antipsicóticos) podem ser consideradas, levando-se em conta 
potencias efeitos colaterais.

The Author(s). This is an open access article published by Thieme under the 
terms of the Creative Commons Attribution 4.0 International License, permitting 
copying and reproduction so long as the original work is given appropriate 
credit (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.1055/s-0043-1777774
PMCID: PMC10756775
PMID: 38157881 [Indexed for MEDLINE]

Conflict of interest statement: Ther is no conflict of interest to declare.